German multinational Fresenius Kabi, which has completed the take-over of Dabur Pharma, would invest Rs 190 crore in the next couple of years to double the capacity of active pharmaceutical ingredients (API) plant and expand the oncology business globally.

Also, the company is working on increasing the business of Dabur Pharma to regulated markets such as Europe and North America. Fresenius Kabi is also learned to work to bag approval from the US Food and Drug Administration (FDA) for its Indian arm's formulation facility in Baddi, Himachal Pradesh.

"We will invest up to EUR 30 million to double the capacity of API manufacturing facility of Dabur Pharma located in Kolkata and also in getting regulatory approvals for newly built formulation plant in Baddi," said, Rainer Baule, president and chief executive officer (CEO), Fresenius Kabi.

The company plans to use the existing formulation manufacturing facility for supplying products to regulated markets of Europe and North America where Fresenius Kabi has a strong distribution and sales network.

The company disclosed that it was interested in a strategic buyer to offload the one per cent additional stake as per the necessary regulation of securities and exchange board of India (SEBI). The company is currently holding talks with some in this regard. Fresenius Kabi acquired 73.27 per cent in Dabur Pharma from its promoters and certain other shareholders in April. Apart, Fresenius Kabi made an open offer for an additional 17.6 per cent stake in the firm. As a result, now Fresenius Kabi has 90.9 per cent stake in Dabur. But according to SEBI guidelines, for any listed firm promoters can hold only up to 89.9 per cent stake. Therefore the company is looking to sell around one per cent stake.

In another development, Fresenius has replaced seven members of the board. While Satish Kulkarni, who was earlier the marketing head of Fresenius Kabi Asia Pacific region replaced Ajay Vij as the CEO of Dabur Pharma, Rakesh Bhargava, the managing director and CEO of Fresenius Kabi India, has been appointed as the chairman of Dabur Pharma.